| Year |
Citation |
Score |
| 2013 |
Vellano CP, Brown NE, Blumer JB, Hepler JR. Assembly and function of the regulator of G protein signaling 14 (RGS14)·H-Ras signaling complex in live cells are regulated by Gαi1 and Gαi-linked G protein-coupled receptors. The Journal of Biological Chemistry. 288: 3620-31. PMID 23250758 DOI: 10.1074/Jbc.M112.440057 |
0.643 |
|
| 2012 |
McCoy KL, Gyoneva S, Vellano CP, Smrcka AV, Traynelis SF, Hepler JR. Protease-activated receptor 1 (PAR1) coupling to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino acids within the receptor second intracellular loop. Cellular Signalling. 24: 1351-60. PMID 22306780 DOI: 10.1016/J.Cellsig.2012.01.011 |
0.64 |
|
| 2011 |
Vellano CP, Lee SE, Dudek SM, Hepler JR. RGS14 at the interface of hippocampal signaling and synaptic plasticity. Trends in Pharmacological Sciences. 32: 666-74. PMID 21906825 DOI: 10.1016/J.Tips.2011.07.005 |
0.599 |
|
| 2011 |
Vellano CP, Maher EM, Hepler JR, Blumer JB. G protein-coupled receptors and resistance to inhibitors of cholinesterase-8A (Ric-8A) both regulate the regulator of g protein signaling 14 RGS14·Gαi1 complex in live cells. The Journal of Biological Chemistry. 286: 38659-69. PMID 21880739 DOI: 10.1074/Jbc.M111.274928 |
0.688 |
|
| 2011 |
Vellano CP, Shu FJ, Ramineni S, Yates CK, Tall GG, Hepler JR. Activation of the regulator of G protein signaling 14-Gαi1-GDP signaling complex is regulated by resistance to inhibitors of cholinesterase-8A. Biochemistry. 50: 752-62. PMID 21158412 DOI: 10.1021/Bi101910N |
0.685 |
|
| 2010 |
Lee SE, Simons SB, Heldt SA, Zhao M, Schroeder JP, Vellano CP, Cowan DP, Ramineni S, Yates CK, Feng Y, Smith Y, Sweatt JD, Weinshenker D, Ressler KJ, Dudek SM, et al. RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory. Proceedings of the National Academy of Sciences of the United States of America. 107: 16994-8. PMID 20837545 DOI: 10.1073/Pnas.1005362107 |
0.54 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2018 |
Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, et al. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell. 33: 401-416.e8. PMID 29533782 DOI: 10.1016/j.ccell.2018.01.019 |
0.21 |
|
| 2018 |
Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, Hua X, Vellano CP, Woessner R, Sahni N, Scott KL, Mills GB. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nature Communications. 9: 4583. PMID 30389923 DOI: 10.1038/S41467-018-06949-W |
0.159 |
|
| 2017 |
Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine. 9. PMID 28566428 DOI: 10.1126/Scitranslmed.Aal5148 |
0.156 |
|
| 2021 |
Donati G, Ravà M, Filipuzzi M, Nicoli P, Cassina L, Verrecchia A, Doni M, Rodighiero S, Parodi F, Boletta A, Vellano CP, Marszalek JR, Draetta GF, Amati B. Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Molecular Oncology. PMID 34632715 DOI: 10.1002/1878-0261.13115 |
0.148 |
|
| 2017 |
Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, et al. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 31: 225-239. PMID 28196595 DOI: 10.1016/J.Ccell.2017.01.005 |
0.139 |
|
| 2020 |
Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, ... ... Vellano CP, et al. BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discovery. PMID 32816843 DOI: 10.1158/2159-8290.Cd-20-0142 |
0.139 |
|
| 2021 |
Jewell BE, Xu A, Zhu D, Huang MF, Lu L, Liu M, Underwood EL, Park JH, Fan H, Gingold JA, Zhou R, Tu J, Huo Z, Liu Y, Jin W, ... ... Vellano C, et al. Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome. Plos Genetics. 17: e1009971. PMID 34965247 DOI: 10.1371/journal.pgen.1009971 |
0.129 |
|
| 2017 |
Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances. 3: e1600957. PMID 28439535 DOI: 10.1126/Sciadv.1600957 |
0.126 |
|
| 2018 |
Lee J, Geiss GK, Demirkan G, Vellano CP, Filanoski B, Lu Y, Ju Z, Yu S, Guo H, Bogatzki LY, Carter WE, Meredith RK, Krishnamurthy S, Ding Z, Beechem JM, et al. Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. Molecular & Cellular Proteomics : McP. PMID 29531020 DOI: 10.1074/mcp.RA117.000291 |
0.125 |
|
| 2021 |
Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Advances. 5: 3134-3146. PMID 34424317 DOI: 10.1182/bloodadvances.2020003821 |
0.118 |
|
| 2018 |
Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, ... ... Vellano CP, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 33: 450-462.e10. PMID 29533785 DOI: 10.1016/J.Ccell.2018.01.021 |
0.101 |
|
| 2019 |
Yang H, Tabe Y, Saito K, Yamatani K, Jacamo R, Ma H, Ruvolo V, Zhang Q, Kuruvilla VM, Baran N, Imoto J, Ikeo K, Moriya K, Murakami-Tonami Y, Suzuki K, ... ... Vellano CP, et al. Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML Blood. 134: 911-911. DOI: 10.1182/Blood-2019-125007 |
0.1 |
|
| 2021 |
Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, ... ... Vellano C, et al. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications. 12: 4626. PMID 34330913 DOI: 10.1038/s41467-021-24798-y |
0.093 |
|
| 2018 |
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Vellano CP, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014 |
0.086 |
|
| 2020 |
Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, ... ... Vellano CP, et al. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. Scientific Reports. 10: 17899. PMID 33087803 DOI: 10.1038/s41598-020-74882-4 |
0.083 |
|
| 2023 |
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, et al. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. PMID 36627494 DOI: 10.1038/s41586-022-05632-x |
0.083 |
|
| 2023 |
Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow CA, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Lieb S, Jeschko A, Machado AA, Marszalek ED, Mahendra M, ... ... Vellano CP, et al. Combined KRAS and SOS1 inhibition enhances and extends the anti-tumor response in KRAS -driven cancers by addressing intrinsic and acquired resistance. Biorxiv : the Preprint Server For Biology. PMID 36747713 DOI: 10.1101/2023.01.23.525210 |
0.079 |
|
| 2021 |
Saito K, Zhang Q, Yang H, Yamatani K, Ai T, Ruvolo V, Baran N, Cai T, Ma H, Jacamo R, Kuruvilla VM, Imoto J, Kinjo S, Ikeo K, Moriya K, ... ... Vellano CP, et al. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition. Blood Advances. PMID 34507353 DOI: 10.1182/bloodadvances.2020003661 |
0.079 |
|
| 2019 |
Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, et al. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. 35: 851-867.e7. PMID 31185210 DOI: 10.1016/J.Ccell.2019.05.001 |
0.077 |
|
| 2024 |
Pilie PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sánchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, ... ... Vellano CP, et al. Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38416404 DOI: 10.1158/1078-0432.CCR-23-1763 |
0.077 |
|
| 2019 |
Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Scientific Reports. 9: 1853. PMID 30755715 DOI: 10.1038/S41598-019-38534-6 |
0.076 |
|
| 2022 |
Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Molecular Cancer Research : McR. PMID 36112348 DOI: 10.1158/1541-7786.MCR-22-0250 |
0.071 |
|
| 2021 |
Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, et al. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer. Cancer Research. PMID 34518211 DOI: 10.1158/0008-5472.CAN-20-3242 |
0.07 |
|
| 2022 |
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. PMID 35705814 DOI: 10.1038/s41586-022-04833-8 |
0.07 |
|
| 2015 |
Federico L, Jeong KJ, Vellano CP, Mills GB. Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. Journal of Lipid Research. PMID 25977291 DOI: 10.1194/Jlr.R060020 |
0.068 |
|
| 2017 |
Reuben A, Tetzlaff MT, Spencer C, Ong G, Barker K, Prieto PA, Vellano C, Lee J, Hudgens C, McKean MA, Gopalakrishnan V, Szczepaniak Sloane R, Reddy S, Merritt C, Warren S, et al. Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts). Journal of Clinical Oncology. 35: 9575-9575. DOI: 10.1200/jco.2017.35.15_suppl.9575 |
0.063 |
|
| 2021 |
Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, et al. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Molecular Cancer. 20: 56. PMID 33766033 DOI: 10.1186/s12943-021-01351-5 |
0.061 |
|
| 2023 |
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, ... ... Vellano CP, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature Medicine. PMID 36658425 DOI: 10.1038/s41591-022-02103-8 |
0.059 |
|
| 2019 |
Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Molecular Cancer. 18: 141. PMID 31601234 DOI: 10.1186/s12943-019-1064-5 |
0.059 |
|
| 2022 |
Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, Keun HC, Vellano CP, Marszalek JR, Wedge SR. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. British Journal of Cancer. PMID 35618788 DOI: 10.1038/s41416-022-01848-w |
0.056 |
|
| 2019 |
Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Ileana Dumbrava EE, Pant S, Subbiah V, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, et al. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 37: 3014-3014. DOI: 10.1200/JCO.2019.37.15_SUPPL.3014 |
0.05 |
|
| 2020 |
Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, et al. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers. 12. PMID 33076512 DOI: 10.3390/cancers12102995 |
0.05 |
|
| 2022 |
Ghilardi C, Moreira Barbosa C, Brunelli L, Ostano P, Panini N, Lupi M, Anastasia A, Fiordaliso F, Salio M, Formenti L, Russo M, Arrigoni E, Chiaradonna F, Chiorino G, Draetta GF, ... ... Vellano CP, et al. PGC1α/β EXPRESSION PREDICTS THERAPEUTIC RESPONSE TO OXIDATIVE PHOSPHORYLATION INHIBITION IN OVARIAN CANCER. Cancer Research. PMID 35131872 DOI: 10.1158/0008-5472.CAN-21-1223 |
0.049 |
|
| 2019 |
Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P. Identification and validation of a prognostic proteomic signature for cervical cancer. Gynecologic Oncology. PMID 31477280 DOI: 10.1016/j.ygyno.2019.08.021 |
0.049 |
|
| 2017 |
McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY. Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. Npj Systems Biology and Applications. 3: 8. PMID 28649435 DOI: 10.1038/s41540-017-0011-6 |
0.048 |
|
| 2021 |
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, et al. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34518313 DOI: 10.1158/1078-0432.CCR-21-1656 |
0.038 |
|
| 2020 |
Chen D, Barsoumian HB, Fischer G, Yang L, Verma V, Younes AI, Hu Y, Masropour F, Klein K, Vellano C, Marszalek J, Davies M, Cortez MA, Welsh J. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. Journal For Immunotherapy of Cancer. 8. PMID 32581056 DOI: 10.1136/jitc-2019-000289 |
0.036 |
|
| Hide low-probability matches. |